RGEN - Repligen and Navigo announce launch of affinity resin for COVID-19 vaccine purification

Repligen (RGEN) and protein engineering company Navigo Proteins announce that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines.The resin could help COVID-19 vaccine manufacturers with a high purity capture step, decreasing processing time and significantly improving overall yield in the production of these  vaccines, the companies said.NGL COVID-19 Spike Protein Affinity Resin will be manufactured and marketed by Repligen.

For further details see:

Repligen and Navigo announce launch of affinity resin for COVID-19 vaccine purification